Ampicillin-cloxacillin intramammary infusion veterinary grade API is a dual-active pharmaceutical input composed of ampicillin sodium or ampicillin trihydrate and cloxacillin sodium monohydrate, standardised to anhydrous antibiotic activity. The blend is supplied for downstream manufacture of intramammary suspensions, injectable solutions after reconstitution, tablets, capsules, oral powders, granules, feed premixes, and soluble drinking-water formulations. The combination pairs the wider Gram-positive and Gram-negative spectrum of ampicillin with the β-lactamase-stable isoxazolyl penicillin cloxacillin; this is intended to preserve activity against penicillinase-producing staphylococci associated with bovine mastitis and other veterinary infections. For intramammary use, the API is often specified in a mass ratio of 1:2.67, corresponding to 75 mg ampicillin and 200 mg cloxacillin per single-dose syringe when formulated. The material is not a finished injection and must be suspended or dissolved in a suitable vehicle, subjected to sterility assurance processes where required, and filled in accordance with the target species and route.

Three physical grades appear in supplier documentation. The sterile micronised grade is intended for aseptic suspension preparation and is controlled for sterility, bacterial endotoxins, particulate matter, and residual moisture. The non-sterile oral grade is used for direct-compression tablets, capsules, and dry powders, and is released by bioburden, water content, and blend uniformity. The soluble premix grade is formulated with a carrier such as lactose monohydrate or dextrose to support distribution in feed or drinking water. Vendor model designations are not harmonised; they typically encode the ampicillin-to-cloxacillin ratio, salt form, micronisation status, and sterility grade. Purchasing documents should reference the intended dosage form so that the supplier assigns the correct model code for sterile intramammary use versus non-sterile oral use.

What Distinguishes a Sterile Intramammary-Grade Ampicillin-Cloxacillin Blend from Non-Sterile Oral API Mixtures?

The principal difference is the manufacturing environment and the release test package. Sterile intramammary-grade material is processed in a classified cleanroom or isolator system, typically EU GMP Grade A within Grade B, and must pass USP <71> sterility testing. If the product is terminally sterilised, the sterilisation dose or cycle must be validated to avoid excessive β-lactam degradation. Non-sterile oral blends are produced in contained solids-handling rooms and are not required to be sterile; instead, acceptance criteria include total aerobic microbial count, total combined yeasts and moulds, and absence of specified pathogens. Endotoxin is route-specific. A sterile injectable beta-lactam monograph may set a limit around 0.25 EU/mg, but for an intramammary infusion the limit must be derived from the maximum syringe dose and species body weight. Oral premix grades do not require an endotoxin limit unless a species-specific justification or relevant pharmacopoeial monograph imposes one.

Particle-size control is also different. The sterile intramammary powder is frequently jet-milled to a d90 of 25 µm or less to provide smooth passage through the teat canal and uniform suspension in the oily or aqueous vehicle. A non-sterile tablet or capsule blend can be coarser, with particle-size acceptance based on dissolution or content uniformity rather than cannula passage. Packaging differs as well: the sterile grade is sealed in moisture-impermeable aluminium pouches under nitrogen, with desiccant, while the oral grade may be double-lined fibre drums if moisture uptake remains below the release limit. In both cases, ampicillin sodium is hygroscopic and cloxacillin sodium undergoes surface hydrolysis in humid conditions; open handling should be limited to controlled relative humidity, and dispensing at more than 60% RH without a dry-air isolator is not recommended.

Physicochemical Release Limits for Dual β-Lactam Veterinary API

Release testing is built around the separate monographs for ampicillin sodium or trihydrate and cloxacillin sodium, with additional blend-specific methods for ratio confirmation and dissolution. The certificate of analysis should report both active contents as anhydrous equivalents, water content by Karl Fischer, pH of a defined aqueous dispersion, related substances, residual solvents, and the particle-size distribution if the material is intended for sterile suspensions. Table 1 lists the core release parameters commonly applied to this dual-active material. The acceptance ranges are not a substitute for a product-specific dossier; manufacturers should justify all limits against pharmacopoeial monographs or a veterinary technical file.

A stability-indicating reversed-phase HPLC method is used to quantify both β-lactam components in the presence of their hydrolysis products. A typical setup is a C18 column of 250 mm length and 5 µm particle size, with a phosphate buffer and acetonitrile gradient, ultraviolet detection at 230 nm, and a column temperature of 25 °C to 30 °C. Method validation includes specificity against cloxacillin dimer and ampicillin degradation peaks, linearity across 80% to 120% of the target concentration, and precision with relative standard deviation ≤ 2.0% for replicate injections. For finished intramammary suspensions, extraction from the oily vehicle may require dilution with a solvent system such as acetonitrile and phosphoric acid before injection; recovery should be demonstrated at 95% to 105%.

Tablet and capsule manufacture with this dual API is dominated by moisture control. Direct compression is used where possible; if granulation is required, dry roller compaction is preferred over high-shear wet granulation because ampicillin sodium is susceptible to hydrolysis in aqueous granulation fluid. Roller compaction on a side-sealed roll press with a roll diameter of 200 mm to 300 mm and a gap of 2 mm to 4 mm can provide ribbons for milling; the exact pressure depends on the filler and the active ratio. A typical dry blend contains microcrystalline cellulose, crospovidone or sodium starch glycolate, and magnesium stearate, with a target tapped bulk density of 0.45 g/mL to 0.65 g/mL. The mixed blend should not be stored in open bins for more than 24 h if the room humidity is above 50%.

Injectable dosage forms are prepared aseptically from the sodium salts because ampicillin trihydrate has insufficient aqueous solubility for high-strength parenteral solutions. The combined solution is sterile-filtered through a 0.22 µm filter after dissolution in water for injection. The holding time before filtration is limited because ampicillin undergoes pH- and temperature-dependent degradation; solutions held at 25 °C for more than 4 h may show measurable assay loss. The pH is maintained above 6.0 to avoid cloxacillin precipitation, but strongly alkaline conditions above 9.0 accelerate β-lactam ring opening. If the finished product is lyophilised, the moisture content is held below 1.0% and the cake is stored under vacuum or nitrogen.

For intramammary infusion, the sterile blend is dispersed in a non-aqueous or aqueous vehicle containing thickening agents, antioxidants, and preservatives as authorised. The final suspension is non-Newtonian and pseudoplastic; Brookfield viscosity at 20 rpm and 25 °C may fall between 300 mPa·s and 1,200 mPa·s, but this range is product-specific and must be confirmed by stability. Recirculation during filling should use a low-shear lobe pump rather than a high-shear centrifugal pump to prevent particle-size attrition and air entrainment. The filling line should maintain an oxygen headspace of ≤ 2% and a room relative humidity of ≤ 30% where possible. In-process checks include syringe weight, viscosity, active content, and reconstituted particle size.

For oral powders, granules, and feed premixes, the dual API is blended with a suitable carrier such as lactose monohydrate, dextrose, or maltodextrin. A ribbon blender or gravity blender is operated at 50% to 70% of gross volume, with mixing time validated to produce a content uniformity CV of ≤ 5.0%. For feed premix, the mixture is diluted in a two-step process, and the final feed concentration may be expressed in kilograms of premix per tonne of complete feed, depending on the authorised indication. Feed processing at elevated temperature requires assay verification because β-lactam activity can decline during steam conditioning above 70 °C; published data for this specific configuration is limited and should be generated for the intended matrix.

When the Dual API Is Processed into Non-Sterile Oral Granules and Soluble Premix Powders

When the target dosage form is an oral granule or soluble powder rather than a sterile suspension, the process risk shifts from sterility assurance to cross-contamination control and blend segregation. Penicillin dust is controlled by downflow booths and HEPA-filtered exhaust; dedicated or validated segregated production equipment is normally required to prevent carryover into non-β-lactam products. If dry granulation is used, the compacted ribbons are milled through a 0.8 mm to 1.25 mm screen and sieved. Wet granulation is avoided unless a non-aqueous binder such as isopropyl alcohol or ethanol is used and the residual solvent after drying is controlled under VICH GL18.

Content uniformity failures in this step are often caused by segregation of fine ampicillin sodium from coarser cloxacillin particles during transfer. Air-jet milling or forced sieving can narrow the distribution; a release specification that includes d10, d50, and d90 is more informative than d50 alone. Bulk blend samples should be taken from multiple positions, and the acceptance criterion for content uniformity is often 90.0% to 110.0% of the targeted ratio with a relative standard deviation ≤ 5.0%. Once packed in sachets or drums, the product is stored below 25 °C and protected from moisture.

Compared with single-active ampicillin or cloxacillin materials, the dual API changes the formulation and regulatory calculation. Table 2 summarises the standard distinctions at the input-material level.

The dual β-lactam API is not compatible with all water-based vehicles. Strongly acidic solutions below pH 4.5 can precipitate cloxacillin acid and reduce suspension uniformity. Strong oxidising agents, peroxide residues, and copper ions can accelerate degradation. Aminoglycoside antibiotics should not be combined in the same aqueous vehicle unless a validated compatibility study demonstrates the absence of mutual inactivation; penicillins can open the β-lactam ring and inactivate aminoglycosides. Re-drying of opened product is not recommended because non-uniform heat transfer can form hot spots and degrade the ampicillin component while leaving residual moisture in the cloxacillin fraction. If the handling room exceeds 60% relative humidity, use of a nitrogen purge or dry-air isolator is required to protect the sodium salts. For food-producing animals, the withdrawal period is determined by the finished product and must consider both actives and any marker residue selected by the regulatory authority.